14/03/2026
Insightful session in Bathinda! đŠş
I had the pleasure of delivering a health talk on MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)âa condition many still recognize by its former name, fatty liver.
What made this session particularly engaging was the audience: a sharp group of fellow gastroenterologists and gastro-surgeons. Itâs always rewarding to dive deep into the clinical nuances of liver health with peers who are on the front lines of digestive care. đ
Key Discussion Highlights:
The Shift to MASLD: Moving beyond the âfatty liverâ label to focus on the metabolic drivers behind the disease.
The Future of Pharmacotherapy: There was significant curiosity surrounding the role of newer medications, specifically the buzz around GLP-1 receptor agonists like Ozempic. đ¨đťââď¸
Clinical Integration: How these metabolic treatments might change the landscape for patients who previously had limited pharmacological options.
A big thank you to all the specialists who attended and contributed to the vibrant Q&A session!